Peer Review History

Original SubmissionDecember 4, 2023
Decision Letter - Violante Di Donato, Editor

PONE-D-23-39011Female sexual function index for screening of female sexual dysfunction using DSM-5-TR criteria in Thai women: A prospective cross-sectional diagnostic studyPLOS ONE

Dear Dr. Khanuengkitkong,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Feb 09 2024 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Violante Di Donato, Ph.D,M.D.

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. We note that the grant information you provided in the ‘Funding Information’ and ‘Financial Disclosure’ sections do not match. 

When you resubmit, please ensure that you provide the correct grant numbers for the awards you received for your study in the ‘Funding Information’ section.

3. Thank you for stating the following financial disclosure: "This work was supported by the Faculty of Medicine, Prince of Songkla University."

Please state what role the funders took in the study.  If the funders had no role, please state: "The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."

If this statement is not correct you must amend it as needed.

Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf.

4. We note that your Data Availability Statement is currently as follows: "All relevant data are within the manuscript and its Supporting Information files."

Please confirm at this time whether or not your submission contains all raw data required to replicate the results of your study. Authors must share the “minimal data set” for their submission. PLOS defines the minimal data set to consist of the data required to replicate all study findings reported in the article, as well as related metadata and methods (https://journals.plos.org/plosone/s/data-availability#loc-minimal-data-set-definition).

For example, authors should submit the following data:

- The values behind the means, standard deviations and other measures reported;

- The values used to build graphs;

- The points extracted from images for analysis.

Authors do not need to submit their entire data set if only a portion of the data was used in the reported study.

If your submission does not contain these data, please either upload them as Supporting Information files or deposit them to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. For a list of recommended repositories, please see https://journals.plos.org/plosone/s/recommended-repositories.

If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially sensitive information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent. If data are owned by a third party, please indicate how others may request data access.

5. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

Additional Editor Comments:

Dear Khanuengkitkong

the topic of the present article titled “Female sexual function index for screening of female sexual dysfunction using DSM-5-TR criteria in Thai women: A prospective cross-sectional diagnostic study" is very interesting, the paper and the aim falls within the scope of the journal but the article needs major improvements.

The introduction, material and method section and tables should be modified and improved.

The manuscript should be organized better and English should be improved.

I suggest improving the manuscript with the reviewers' comments.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Partly

Reviewer #4: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

Reviewer #4: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

Reviewer #4: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

Reviewer #4: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: This is a very interesting article covering female sexual dysfunction in an Asian country which is highly likely to be affected with eastern culture.

The Introduction have addressed nicely the novelty of this study.

There are a few points that need to be addressed:

1. The exclusion criteria includes having a partner with sexual dysfunction. Was it all types and degree of sexual dysfunction? How many subjects were excluded due to this criteria?

Question 10 of the questionnaire assessed partner information. Please clarify what kind of information.

Sexual partner's dysfunction may affect the female sexual function and vice versa. The data on the partner's sexual function and how it differed from the FSD group and non FSD group might be interesting to reveal.

2. The distress score is actually an overall score and did not distinguish each domain/category of FSD. The authors have addressed this as a limitation of this study.

Distress score for each domain is important because in eastern cultures many women are experiencing FSD, however it does not actually causing them distress because sex usually is a taboo matter, it is considered only an obligation to be fulfilled instead of being enjoyed and as long as the women can function in other areas, complaints of FSD are not considered something that would affect their overall quality of life. This should be mentioned in the discussion.

3. The prevalence of GPPD, FOD and FSAID in this study is higher compared to previous studies done in Chile and Brazil. The authors should also compare with the data form eastern/neighboring countries of Thailand and elaborate more on the discrepancies if any.

Reviewer #2: The manuscript authored by dr Patthamaphorn Chongcharoen and colleagues aim to define the optimal Thai FSFI cutoff point for screening FSD using DSM-5-TR criteria in Thai women. Also, a second objective was to determine the prevalence of FSD in Thai women using DSM-5-TR criteria

The article is good and the chapters (Introduction, Material and Methods, Results, Discussions and Conclusions) are well written.

The study is a prospective cross-sectional diagnostic study which include a significant number of 500 sexually active women. Each women was evaluated by FSFI and a semi-structured interview about their overall distress defined by DSM-5-TR criteria.

The results are clear presented in 4 tables and compared in table 5 with resulte from other studies.

The discussions are complete.

I propose to accept the article for publication without changes

Reviewer #3: Thank you for the privilege of reviewing this manuscript. This manuscript reports on a validation study of the Thai version of the FSFI to assess female sexual function. Overall, this paper is well-written; a few minor edits are suggested below, given the lack of a priori criteria.

Table 4

1. Cutoff scores of 23.1, 24.1, and 23.5 are listed, but not for the same groups of participants. Please include all observed cutoff scores for: all participants, age ≤40 years, age > 40 years, premenopause, and postmenopause. It is difficult to see the benefits and limitations of the listed cutoff scores because information is omitted (e.g., women >40 years with a cutoff of 23.1, etc.).

Discussion

A cutoff score of 23.1 for screening of FSD using the DSM-5-TR criteria was considered best; however, this resulted in a sensitivity of 75.6 and specificity of 67.7, which seem a bit low. Nearly a quarter of cases are being missed with a sensitivity of only 75.6, and a third of identified cases are incorrectly identified (specificity of 67.7).

2. Please suggest secondary screeners or alternative approaches to utilizing this screener, given the low sensitivity and specificity values.

3. Please include as a limitation the lack of predetermined criteria to identify appropriate cutoff scores.

4. Please reference other measures with similar psychometric properties given the utilized cutoff score; if other measures do not use a cutoff score with 76% sensitivity and 68% specificity, please justify why a cutoff score of 23.1 is suitable as a screener for this particular measure.

Reviewer #4: I read with great interest the Manuscript titled “Female sexual function index for screening of female sexual dysfunction using DSM-5- TR criteria in Thai women: A prospective cross-sectional diagnostic study “. In my opinion, this topic analyzed is interesting enough to attract readers’ attention.

Although the manuscript can be considered already of good quality, I would suggest following recommendations:

- I suggest a round of language revision, in order to correct few typos and improve readability.

- The authors could extend and improved the discussion by evaluating and citing current evidence about possible therapeutic strategy to improve quality of life and symptoms of female sexual functions. I would be glad if the authors discuss this important point, referring to: PMID 32252962 and 36037664.

Because of these reasons, the article should be revised and completed. Considering all these points, I think it could be of interest to the readers and, in my opinion, it deserves the priority to be published after minor revisions.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

Reviewer #3: No

Reviewer #4: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Attachments
Attachment
Submitted filename: PONE-D-23-39011 review.pdf
Revision 1

Editor’s comment

(1) Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

Response: Thank you for your prompt response and valuable feedback.

We have ensured that our revised manuscript aligns with these requirements and have made the necessary changes to meet PLOS ONE's standards. Thank you once again for your guidance and support.

(2) We note that the grant information you provided in the ‘Funding Information’ and ‘Financial Disclosure’ sections do not match.

When you resubmit, please ensure that you provide the correct grant numbers for the awards you received for your study in the ‘Funding Information’ section.

(3) Please state what role the funders took in the study. If the funders had no role, please state: "The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."

Response: Thank you for bringing this to our attention. We appreciate your thorough review, and acknowledge the discrepancy between the grant information provided in the 'Funding Information' and in the 'Financial Disclosure' sections.

In the revised submission, we have ensure that the correct grant numbers for the awards received for our study have been accurately reflected in the 'Funding Information' section. We apologize for any confusion caused by this oversight, and appreciate your diligence in ensuring the accuracy of our manuscript.

Funding: The research was financially supported by the Faculty of Medicine, Prince of Songkla University. Grant 65-086-1, PI: P. Chongcharoen. The funders had no role in the study design, in the data collection and analysis, in the decision to publish, or in the preparation of the manuscript.

Competing interests: The authors have declared that no competing interests exist.

Thank you for your time and consideration.

(4) We note that your Data Availability Statement is currently as follows: "All relevant data are within the manuscript and its Supporting Information files."

Response : Thank you for bringing this to our attention. We acknowledge the note regarding our Data Availability Statement, which currently states: "All relevant data are within the manuscript and its Supporting Information files."

Upon your recommendation, we will submit the minimal dataset required to replicate all study findings reported in the article.

(5) Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

Response: Due to the retraction of the paper, the citation to the following article:

Mercer CH, Fenton KA, Johnson AM, Wellings K, Macdowall W, McManus S, et al. Sexual function problems and help seeking behaviour in Britain: National probability sample survey. BMJ. 2003;327: 426–427. doi: 10.1136/bmj.327.7412.426

has been removed. Instead, a new citation (Reference 5) has been added to the revised manuscript for the following study:

Amidu N, Owiredu WKBA, Woode E, Addai-Mensah O, Quaye L, Alhassan A, et al. Incidence of sexual dysfunction: a prospective survey in Ghanaian females. Reprod Biol Endocrinol. 2010;8:106. doi: 10.1186/1477-7827-8-106.

Reviewer 1

(1) The exclusion criteria includes having a partner with sexual dysfunction. Was it all types and degree of sexual dysfunction? How many subjects were excluded due to this criteria?

Question 10 of the questionnaire assessed partner information. Please clarify what kind of information.

Sexual partner's dysfunction may affect the female sexual function and vice versa. The data on the partner's sexual function and how it differed from the FSD group and non FSD group might be interesting to reveal.

Response: In answer to your question, only patients who met the inclusion criteria but not the exclusion criteria were included. A few prospective participants were excluded after an interview in which the presence of male hypoactive sexual desire disorder, premature ejaculation, delayed ejaculation, or erectile dysfunction (in any degree) in the sexual partner was assessed. Question 10 of the questionnaire specifically assessed irregular cohabitation with partners, which could have a negative impact in terms of stress levels and the frequency of sexual activity. The results revealed no significant effect of irregular cohabitation with partners. In our revised manuscript, we have added a detailed description of Question 10 in the second paragraph of the Materials and Methods section.

(2) The distress score is actually an overall score and did not distinguish each domain/category of FSD. The authors have addressed this as a limitation of this study.

Distress score for each domain is important because in eastern cultures many women are experiencing FSD, however it does not actually causing them distress because sex usually is a taboo matter, it is considered only an obligation to be fulfilled instead of being enjoyed and as long as the women can function in other areas, complaints of FSD are not considered something that would affect their overall quality of life. This should be mentioned in the discussion.

The distress score is actually an overall score and did not distinguish each domain/category of FSD. The authors have addressed this as a limitation of this study.

Response: We appreciate the reviewer's insightful comments regarding the distress score in our study. We acknowledge that the distress score provided in our analysis is an overall score and does not distinguish between domains/categories of FSD. As rightly pointed out, this limitation has been addressed in the Discussion section of our revised manuscript (third paragraph).

(3) The prevalence of GPPPD, FOD and FSAID in this study is higher compared to previous studies done in Chile and Brazil. The authors should also compare with the data form eastern/neighboring countries of Thailand and elaborate more on the discrepancies if any.

Response: We appreciate the reviewer's observation regarding the prevalence of GPPPD, FOD, and FSAID in our study compared to previous research conducted in Chile and Brazil. We acknowledge the importance of providing a comprehensive analysis, including a comparison with data from other Eastern countries, including those neighboring to Thailand. In our revised manuscript, we have incorporated a detailed comparison with relevant studies from this regions to elucidate the variations observed in the prevalence of GPPPD, FOD, and FSAID. This comparison can be found in the eighth paragraph of the Discussion section.

Reviewer 2

The manuscript authored by Dr Patthamaphorn Chongcharoen and colleagues aim to define the optimal Thai FSFI cutoff point for screening FSD using DSM-5-TR criteria in Thai women. Also, a second objective was to determine the prevalence of FSD in Thai women using DSM-5-TR criteria

The article is good and the chapters (Introduction, Material and Methods, Results, Discussions and Conclusions) are well written.

The study is a prospective cross-sectional diagnostic study which include a significant number of 500 sexually active women. Each women was evaluated by FSFI and a semi-structured interview about their overall distress defined by DSM-5-TR criteria.

The results are clear presented in 4 tables and compared in table 5 with result from other studies.

The discussions are complete.

I propose to accept the article for publication without changes.

Response:

Thank you very much for your positive feedback and thorough review of our manuscript. We appreciate your kind remarks regarding the clarity and structure of the manuscript sections. We are particularly glad that the results, presented in tables and compared in Table 5 with findings from other studies, have met your expectations.

Your acknowledgment of the completeness of the Discussion section is encouraging, and we are pleased that the study design and methods were well-received. We are grateful for your suggestion to accept the article for publication without changes. Thank you for your time and valuable insight.

Reviewer 3

(1) Cutoff scores of 23.1, 24.1, and 23.5 are listed, but not for the same groups of participants. Please include all observed cutoff scores for: all participants, age ≤40 years, age > 40 years, premenopause, and postmenopause. It is difficult to see the benefits and limitations of the listed cutoff scores because information is omitted (e.g., women >40 years with a cutoff of 23.1, etc.).

A cutoff score of 23.1 for screening of FSD using the DSM-5-TR criteria was considered best; however, this resulted in a sensitivity of 75.6 and specificity of 67.7, which seem a bit low. Nearly a quarter of cases are being missed with a sensitivity of only 75.6, and a third of identified cases are incorrectly identified (specificity of 67.7).

Response: We conducted subgroup analyses based on cutoff values derived from the total FSFI score and various characteristics. Our findings revealed that among women aged over 40 years, the optimal cutoff was 24.1, demonstrating a sensitivity of 59.3% and a specificity of 82%. For the premenopausal group, the optimal cutoff was 23.5, with a sensitivity of 76.5% and a specificity of 62.6%. Additionally, in other groups, such as those aged 40 years or younger and those in postmenopause, the optimal cutoff was identified as 23.1 (Table 4). We have included these optimal cutoff values in the fifth paragraph of the Results section in our revised manuscript.

The data we analyzed is shown in the table below.

Character Cutoff score Sensitivity Specificity PPV NPV LR+ LR- AUC

All participants 23.1 75.6 67.7 77.7 65.1 2.3 0.4 0.76

23.5 72.6 69.7 78.1 63.1 2.4 0.4 0.76

24.1 68.2 71.6 78.2 60.3 2.4 0.4 0.76

Character Cutoff score Sensitivity Specificity PPV NPV LR+ LR- AUC

Age ≤40 years 23.1 83.3 54.4 79.1 61.2 1.8 0.3 0.73

23.5 79.6 57.8 79.6 57.8 1.9 0.4 0.73

24.1 73.7 58.9 78.7 52.0 0.8 0.4 0.73

Character Cutoff score Sensitivity Specificity PPV NPV LR+ LR- AUC

Age >40 years 23.1 62.8 78.4 74.7 67.4 2.9 0.8 0.75

23.5 61.1 79.3 75.0 66.7 2.9 0.5 0.75

24.1 59.3 82.0 77.0 66.4 3.2 0.5 0.75

Character Cutoff score Sensitivity Specificity PPV NPV LR+ LR- AUC

Premenopause 23.1 79.2 60.1 78.6 61.0 2.0 0.3 0.74

23.5 76.5 62.9 79.2 59.2 2.1 0.4 0.74

24.1 71.6 65.7 79.4 55.6 2.1 0.4 0.74

Character Cutoff score Sensitivity Specificity PPV NPV LR+ LR- AUC

Postmenopause 23.1 48.6 86.2 68.0 73.5 3.5 0.6 0.69

23.5 42.9 86.2 65.2 71.4 3.1 0.7 0.69

24.1 42.9 86.2 65.2 71.4 3.1 0.7 0.69

(2) Please suggest secondary screeners or alternative approaches to utilizing this screener, given the low sensitivity and specificity values.

Response: We appreciate the reviewer's insightful comment regarding the low sensitivity and specificity values observed in our screener. Recognizing the importance of improving the screening tool, we are committed to addressing this limitation. In our revised manuscript, we explore and discuss potential secondary screeners or alternative approaches, specifically in the eleventh and twelfth paragraph of the revised Discussion section.

(3) Please include as a limitation the lack of predetermined criteria to identify appropriate cutoff scores.

Response: We appreciate the reviewer's insightful comment regarding the lack of predetermined criteria to identify appropriate cutoff scores in our study. Recognizing the importance of transparency, we have included this as a limitation in our revised manuscript, specifically in the twelfth paragraph of the Discussion section.

(4) Please reference other measures with similar psychometric properties given the utilized cutoff score; if other measures do not use a cutoff score with 76% sensitivity and 68% specificity, please justify why a cutoff score of 23.1 is suitable as a screener for this particular measure.

Response: We appreciate the reviewer's suggestion. In the eleventh paragraph of the revised Discussion section, we have thoroughly discussed this point and included relevant references to measures that align with these criteria.

Reviewer 4

(1) I suggest a round of language revision, in order to correct few typos and improve readability.

Response: Thank you for your constructive feedback. We appreciate your suggestion for a round of language revision to correct typos and improve readability. We have undertaken a thorough review of the text and made the necessary revisions to enhance the overall clarity and readability of the manuscript. Your input is valuable to us. Once again, thank you for your time and thoughtful recommendations.

(2) The authors could extend and improved the discussion by evaluating and citing current evidence about possible therapeutic strategy to improve quality of life and symptoms of female sexual functions. I would be glad if the authors discuss this important point, referring to: PMID 32252962 and 36037664.

Response: We sincerely appreciate the reviewer's insightful comment and guidance. Recognizing the significance of discussing therapeutic strategies to enhance the quality of life and address the symptoms of female sexual dysfunction, we have extended and improved the Discussion section in our revised manuscript. We specifically refer to the provided PMID 32252962 and 36037664 and incorporated the current evidence related to potential therapeutic interventions. Thank you for pointing us towards these relevant references. We have incorporated this additional information into the thirteenth paragraph of our revised Discussion.

Attachments
Attachment
Submitted filename: Response_to_Reviewers.docx
Decision Letter - Violante Di Donato, Editor

Female sexual function index for screening of female sexual dysfunction using DSM-5-TR criteria in Thai women: A prospective cross-sectional diagnostic study

PONE-D-23-39011R1

Dear Dr. Khanuengkitkong,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Violante Di Donato, Ph.D,M.D.

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

The manuscript has been modified with the comments of the reviewers. It is now ready to be published.

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

Reviewer #3: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: All reviewer's comments have been addressed by the authors. I recommend to accept this article to be published.

Reviewer #2: Dear Authiors,

as mentioned at the first review round I agree with publication in this form.

I find your research well done and the questions from the other reviewers also improved the content.

thank you

Reviewer #3: Thank you for the privilege of reviewing this manuscript; all suggested revisions have been adequately made. I have no further reservations towards accepting this submission.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

Reviewer #3: No

**********

Formally Accepted
Acceptance Letter - Violante Di Donato, Editor

PONE-D-23-39011R1

PLOS ONE

Dear Dr. Khanuengkitkong,

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now being handed over to our production team.

At this stage, our production department will prepare your paper for publication. This includes ensuring the following:

* All references, tables, and figures are properly cited

* All relevant supporting information is included in the manuscript submission,

* There are no issues that prevent the paper from being properly typeset

If revisions are needed, the production department will contact you directly to resolve them. If no revisions are needed, you will receive an email when the publication date has been set. At this time, we do not offer pre-publication proofs to authors during production of the accepted work. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few weeks to review your paper and let you know the next and final steps.

Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Violante Di Donato

Academic Editor

PLOS ONE

Open letter on the publication of peer review reports

PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.

We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.

Learn more at ASAPbio .